Global Human Rabies Immune Globulin (HRIG) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Human Rabies Immune Globulin (HRIG) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Human Rabies Immune Globulin (HRIG) is a rabies immunoglobulin obtained by collecting the plasma of a person immunized with a human rabies vaccine and using low-temperature ethanol protein separation or other approved separation and manufacturing processes.

Market Overview:

The latest research study on the global Human Rabies Immune Globulin (HRIG) market finds that the global Human Rabies Immune Globulin (HRIG) market reached a value of USD 578.49 million in 2022. It’s expected that the market will achieve USD 630.14 million by 2028, exhibiting a CAGR of 1.44% during the forecast period.

Human Rabies Immune Globulin (HRIG) Industry Development Trends under COVID-19 Outbreak

Since the outbreak of the epidemic, the global economy has been hit hard. It's the worst global recession in decades, despite massive efforts by governments, backed by fiscal and monetary policies, to fight it. But in the longer term, a severe recession triggered by the pandemic is expected to lead to a prolonged economic downturn by reducing investment. The recession could get worse if the COVID-19 outbreak continues if restrictions on mobility are extended or reintroduced, or if economic activity is disrupted for a prolonged period. Businesses could struggle to repay debt, increased risk aversion could lead to higher borrowing costs, and bankruptcies and defaults could lead to financial crises in many countries.

From the perspective of production, for the Human Rabies Immune Globulin (HRIG) industry, the epidemic has affected the production plans of companies in the Human Rabies Immune Globulin (HRIG) industry. Due to the outbreak of COVID-19, the production and operation of raw materials have been affected, such as the production of plasma raw materials is restricted. This could lead to disruptions in the supply of raw materials for the Human Rabies Immune Globulin (HRIG) industry, thereby affecting the company's production plans. During the outbreak, the pulp collection stations were basically closed. With the relaxation of epidemic prevention and control measures, various blood product manufacturers have gradually resumed plasma collection activities, but overall, the epidemic has had a certain impact on plasma collection activities. On the other hand, due to the impact of the new crown pneumonia epidemic, in order to prevent the further spread of the epidemic, the government issued travel restrictions and related isolation policies, which reduced the management efficiency of enterprises in the industry and affected the company's production plan.

In terms of sales channels, generally speaking, Human Rabies Immune Globulin (HRIG) is mainly sold to hospitals through drug distributors. However, the distribution market of Human Rabies Immune Globulin (HRIG) has been greatly affected due to the restrictions on domestic transportation and personnel movement in many countries during the epidemic. In addition, from a downstream point of view, the COVID-19 epidemic has led to a reduction in residents’ travel time for outdoor activities, prolonged contact with animals at home, and an increased risk of rabies exposure. The demand for Human Rabies Immune Globulin (HRIG) may increase.

Drivers

Benefits of Human Rabies Immune Globulin (HRIG)
The World Health Organization recommends that for class III exposures to the rabies virus, active immunization should be vaccinated immediately. At the same time, rabies immunoglobulin (RIG) should be infiltrated around the wound for passive immunization to obtain a rapid protective effect. Rabies immunoglobulin can directly kill the rabies virus entering the body in a neutralizing manner without the body's response. Therefore, an immediate injection of RIG around a rabid animal bite wound will increase the level of protection against rabies. Two RIGs commonly used are human rabies immunoglobulin (HRIG) and equine rabies immunoglobulin (ERIG). Compared with equine rabies immunoglobulin, HRIG does not have the risk of allergies caused by factors such as heterologous proteins, and the incidence of adverse reactions is relatively lower. So far, human anti-rabies immune globulin has gradually replaced equine rabies immune globulin. Human anti-rabies immunoglobulin has many advantages such as long half-life in the human body (21 days), no need for skin test before injection, and no serum sickness. The advantages and widespread promotion of Human Rabies Immune Globulin (HRIG) are one of the driving factors for the development of the industry.

Industry Limitations

High-quality rabies immune plasma in short supply
The main raw material of Human Rabies Immune Globulin (HRIG) is rabies immune plasma. High-quality immune plasma is very important to the production of Human Rabies Immune Globulin (HRIG). On the one hand, from the perspective of plasma supply, due to factors such as the time cost of the human immune response and the lack of immunized blood donors, the market for rabies immune plasma supply is in short supply. In addition, due to reasons such as unreasonable immunization procedures, outdated virus inactivation technology, and unguaranteed safety of blood sources, many rabies immune plasmas have many deficiencies such as low potency and difficulty to guarantee safety. The production capacity of high-quality rabies immune plasma is very limited. The shortage of high-quality rabies immune plasma has limited the production capacity of Human Rabies Immune Globulin (HRIG), which will be one of the challenges facing the development of the industry.

Region Overview:

In 2022, the share of the Human Rabies Immune Globulin (HRIG) market in China stood at 46.19%.

Company Overview:

Grifols
Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information, and services they need to help them deliver expert medical care. With a network of more than 180 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic, and at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous therapies, clinical nutrition products, and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.
CSL Behring
CSL Behring is a global leader in biotherapeutics. Focused on meeting the needs of patients by using the latest technologies, CSL Behring discovers, develops and delivers innovative therapies to patients in the therapeutic areas of immunology, hematology, cardiovascular and metabolism, respiratory and transplantation. CSL Behring uses three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continuous innovation and continually improve the way products address unmet medical needs and help patients live fulfilling lives.

Grifols is one of the major players operating in the Human Rabies Immune Globulin (HRIG) market, holding a share of 18.33% in 2023.

Segmentation Overview:

100 IU/ml
It means that the product of this specification contains 100 IU of human rabies immunoglobulin per milliliter of solution.
150 IU/ml
It means that the product of this specification contains 150 IU of human rabies immunoglobulin per milliliter of solution.
350 IU/ml
It means that the product of this specification contains 300 IU of human rabies immunoglobulin per milliliter of solution.

By type, 100 IU/ml segment accounted for the largest share of market in 2022.

Application Overview:

Category II Exposure
Minor wounds such as a superficial scratch or abrasion without bleeding would be Category II.
Category III Exposure
Single or multiple transdermal bites or scratches, contamination of mucous membrane or broken skin with saliva from animal licks, exposures due to direct contact with bats (severe exposure)

By application, the Category III Exposure segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Human Rabies Immune Globulin (HRIG) market covered in Chapter 3:

Grifols
Sanofi
Shuanglin Bio-pharmacy
Hualan Bio
Taibang Biologic Group
Kamada
CSL Behring
Sichuan Yuanda Shuyang
Shanghai RAAS
Weiguang Biological

In Chapter 4 and Chapter 14.2, on the basis of types, the Human Rabies Immune Globulin (HRIG) market from 2018 to 2029 is primarily split into:

100 IU/ml
150 IU/ml
350 IU/ml

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Human Rabies Immune Globulin (HRIG) market from 2018 to 2029 covers:

Category II Exposure
Category III Exposure

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)